The existence of human immunodeficiency virus resistance to nucleoside- analog drugs has not been shown

Medical Hypotheses

Volumn 49, Issue 3, 1997, Pages 235-240

  Martinez, M ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE; ZALCITABINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ARTICLE; CROSS RESISTANCE; DRUG SENSITIVITY; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NATURAL SELECTION; PRIORITY JOURNAL; STRAIN DIFFERENCE; STRUCTURAL GENE; VIRUS VIRULENCE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0030756890     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(97)90208-5     Document Type: Article

References (42)

1. Horton R. Truth and heresy about AIDS. NY Rev Books 1996; 43 (23 May): 14-20. Garrett L. New AIDS hope: Drugs, tests seen as way to eradicate virus from body. Newsday 1996; June 14: A04. Garrett L. What we fear: Experts say resistance could develop. Newsday 1996; July 2: B19. Garrett L. The new AIDS cocktails, what we know: A dozen questions and answers. Newsday 1996; July 2: B19.
2. Horton R. Truth and heresy about AIDS. NY Rev Books 1996; 43 (23 May): 14-20. Garrett L. New AIDS hope: Drugs, tests seen as way to eradicate virus from body. Newsday 1996; June 14: A04. Garrett L. What we fear: Experts say resistance could develop. Newsday 1996; July 2: B19. Garrett L. The new AIDS cocktails, what we know: A dozen questions and answers. Newsday 1996; July 2: B19.
3. Horton R. Truth and heresy about AIDS. NY Rev Books 1996; 43 (23 May): 14-20. Garrett L. New AIDS hope: Drugs, tests seen as way to eradicate virus from body. Newsday 1996; June 14: A04. Garrett L. What we fear: Experts say resistance could develop. Newsday 1996; July 2: B19. Garrett L. The new AIDS cocktails, what we know: A dozen questions and answers. Newsday 1996; July 2: B19.
4. Horton R. Truth and heresy about AIDS. NY Rev Books 1996; 43 (23 May): 14-20. Garrett L. New AIDS hope: Drugs, tests seen as way to eradicate virus from body. Newsday 1996; June 14: A04. Garrett L. What we fear: Experts say resistance could develop. Newsday 1996; July 2: B19. Garrett L. The new AIDS cocktails, what we know: A dozen questions and answers. Newsday 1996; July 2: B19.
5. Yarchoan R, Pluda J M, Perno C F, Mitsuya H, Broder S. Antiretroviral therapy of human immunodeficiency virus infection: Current strategies and challenges for the future. Blood 1991; 78: 859-884.
6. Larder B A, Kemp S D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989; 246: 1155-1158.
7. Stephenson J. New anti-HIV drugs and treatment strategies buoy AIDS researchers. J Am Med Assoc 1996; 275: 579-580.
8. Richman D D. Minireview. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother 1993; 37: 1207-1213.
9. Zhu Q Y, Scarborough a, Polsky B, Chou T C. Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 stains. AIDS Res Hum Retroviruses 1996; 12: 507-517.
10. Shafer R W, Kozal M J, Winters M A et al. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis 1994; 169: 722-729.
11. Staszewski S, Miller V, Rehmet S et al. Virological and immunological analysis of triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS 1996; 10: F1-F7.
12. Nielsen C, Bruun L, Mathiesen L R, Pedersen C, Gerstoft J. Development of resistance to zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI, and alternating ZDV/ddI therapy. AIDS 1996; 10: 625-633.
13. Wu S, Liu X, Solorzano M M, Kwock R, Avramis V I. Development of zidovudine (AZT) resistance in Jurkat T cells is associated with decreased expression of the thymidine kinase (TK) gene and hypermethylation of the 5′ end of human TK gene. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8: 1-9.
14. Avramis V I, Kwock R, Solorzano M M, Gomperts E. Evidence of in vitro development of drug resistance to azidothymidine in T-lymphocytic leukemia cell lines (Jurkat E6-1/AZT-100) and in pediatric patients with HIV-1 infection. J Acquir Immune Defic Syndr 1993; 12: 1287-1296.
15. Mohri H, Singh M K, Ching W T W, Ho D D. Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients. Proc Natl Acad Sci USA 1993; 90: 25-29.
16. Kozal M J, Shafer R W, Winters M A, Katzenstein D A, Merigan T C. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis 1993; 167: 526-532.
17. Antonelli G, Turriziani O, Verri A et al. Long-term exposure to zidovudine affects in vitro and in vivo the efficiency of phosphorylation of thymidine kinase. AIDS Res Hum Retroviruses 1996; 12: 223-228.
18. St Clair M H, Martin J L, Tudor-Williams G et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991; 253: 1557-1559.
19. Fitzgibbon J E, Howell R M, Haberzettl C A, Sperber S J, Gocke D J, Dubin D T. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob Agents Chemother 1992; 36: 153-157.
20. Lopez-Galindez C, Rojas J M, Najera R, Richman D D, Perucho M. Characterization of genetic variation and 3′-azido-3′-deoxythymidine-resistance mutations of human immunodeficiency virus by the RNase A mismatch of human immunodeficiency virus by the RNase A mismatch cleavage method. Proc Natl Acad Sci USA 1991; 88: 4280-4284.
21. Kellam P, Boucher C A B, Larder B A. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 1992; 89: 1934-1938.
22. Larder B A, Dary G, Richman D D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243: 1731-1734.
23. de Ronde A, Schuurman R, Goudsmit J, van den Hoek A, Boucher C. First case of new infection with zidovudine-resistant HIV-1 among prospectively studied intravenous drug users and homosexual men in Amsterdam, the Netherlands [correspondence]. AIDS 1996; 10: 231.
24. Lowy I, Caruso M, Goff S P, Klatzmann D. Cellular thymidine kinase activity is required for the inhibition of HIV-1 replication by AZT in lymphocytes. Virology 1994; 200: 271-275.
25. Furman P A, Fyfe J A, St Clair M H et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986; 83: 8333-8337.
26. Hao Z, Cooney D A, Hartman N R et al. Factors determining the activity of 2′,3′-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. Mol Pharmacol 1988; 34: 431-435.
27. Collier L H, Timbury M C, eds. Topley and Wilson's Principles of Bacteriology, Virology and Immunity, 8th edn, Vol. 4. Philadelphia: B.C. Decker, 1990: 215-217.
28. Iversen A K N, Shafer R W, Wehrly K et al. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 1996; 70: 1086-1090.
29. Cooney D A, Dalal M, Mitsuya H et al. Initial studies on the cellular pharmacology of 2′,3′-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol 1986; 35: 2065-2068.
30. Rooke R, Parniak M A, Tremblay M et al. Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: Susceptibility and resistance to other drugs. Antimicrob Agents Chemother 1991; 35: 988-991
31. Lacey S F, Reardon J E, Furfine E S et al. Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3′-azido-3′-deoxythymidine. J Biol Chem 1992; 267: 15789-15794.
32. Land S, Treloar G, McPhee D et al. Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS. J Infect Dis 1990; 161: 326-329.
33. Larder B A, Kellam P, Kemp S D. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro [letter]. Nature 1993; 365: 451-453.
34. Goulden M G, Cammack N, Hopewell P L, Penn C R, Cameron J M. Selection in vitro of an HIV-1 variant resistant to both lamivudine (3TC) and zidovudine [correspondence]. AIDS 1996; 10: 101-102.
35. Balzarini J, Karlsson A, Perez-Perez M-J et al. HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. Virology 1993; 192: 246-253.
36. Najera I, Holguin A, Quinones-Mateu M E et al. Pol gene quasispecies of human immunodeficiency virus: Mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 1995; 69: 23-31.
37. McGavin C H, Land S A, Sebire K L, Hooker D J, Gurusinghe A D, Birch C J. Syncytium-inducing phenotype and zidovudine susceptibility of HIV-1 isolated from post-mortem tissue. AIDS 1996; 10: 47-53.
38. Boucher C A B, Tersmette M, Lange J M A et al. Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet 1990; 336: 585-590.
39. Waqar M A, Evans M J, Manly K F, Hughes R G, Huberman J A. Effects of 2′,3′-dideoxynucleosides on mammalian cells and viruses. J Cell Physiol 1984; 121: 402-408.
40. Ho D D. Viral counts count in HIV infection. Science 1996; 272: 1124-1125.
41. Wei X, Ghosh S K, Taylor M E et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-122.
42. Personal communication with David Rasnick, Arris Pharmaceutical Corp., South San Francisco, CA, August 1996.